Markers | Benign (98) | Malignant (54) | |||||
---|---|---|---|---|---|---|---|
 | Non-Neoplastic HN 52 (%) | Neoplastic FA/HA 46 (%) | Total 98 (%) | FC 22 | PTC 20 | FVPC 12 | Total 54 (%) |
Gal-3 | 8 (15.3%) | 19 (41.3%) | 27(27.5%) | 18 (81.8%) | 18 (90%) | 10 (83.3%) | 46 (85.1%) |
RET | 9 (17.3%) | 21 (45.6%) | 30(30.6%) | 16 (72.7%) | 18 (90%) | 11 (91.7%) | 45 (83.3%) |
HBME-1 | 9 (17.3%) | 26 (56.5%) | 35(35.7%) | 18 (81.8%) | 18 (90%) | 11 (91.7%) | 47 (87%) |
CK-19 | 8(15.3%) | 23 (50%) | 31(31.6%) | 19 (86.3%) | 17 (85%) | 10 (83.3%) | 47 (85.1%) |